Loading
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
Site: Liver and intrahepatic bile ducts (shared total; subtype split not reported). World: 866,136 new cases a year.
| # | Country | New cases | Incidence ASR |
|---|---|---|---|
| 1 | China | 367,657 | |
| 2 | United States of America | 43,492 | |
| 3 | Japan | 41,388 | |
| 4 | India | 38,703 | |
| 5 | Egypt | 27,946 | |
| 6 | Thailand | 27,936 | |
| 7 | Viet Nam | 24,502 | |
| 8 | Indonesia | 23,805 | |
| 9 | Korea, Republic of | 14,791 | |
| 10 | Brazil | 13,599 |
ICD-10 C22 combines hepatocellular carcinoma with intrahepatic cholangiocarcinoma (HCC is roughly 75-85% of the total).
Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.
| # | Country | New cases | Deaths |
|---|---|---|---|
| 1 | China | 367,657 | 316,544 |
| 2 | United States of America | 43,492 | 30,931 |
| 3 | Japan | 41,388 | 26,420 |
| 4 | India | 38,703 | 36,953 |
| 5 | Egypt | 27,946 | 26,971 |
| 6 | Thailand | 27,936 | 27,143 |
| 7 | Viet Nam | 24,502 | 23,333 |
| 8 | Indonesia | 23,805 | 23,383 |
| 9 | Korea, Republic of | 14,791 | 12,595 |
| 10 | Brazil | 13,599 | 13,041 |
World: 866,136 new cases and 758,725 deaths a year (GLOBOCAN 2022).
New York · cancer center | United States | 0 | 5,120 | 95,936 | #1 | ||
| South Korea | none recorded | 0 | 1,177 | 18,820 | none recorded | #4 | |
Rochester, MN · hospital | United States | 0 | 4,572 | 48,202 | #5 | ||
Villejuif · cancer center | France | none recorded | 0 | 1,862 | 31,707 | #6 | |
Seoul · hospital | South Korea | none recorded | 0 | 1,612 | 26,269 | #8 | |
Baltimore · cancer center | United States | 0 | 2,962 | 42,161 | #10 | ||
Melbourne · cancer center | Australia | none recorded | 0 | 1,554 | 24,520 | #14 | |
Heidelberg · cancer center | Germany | none recorded | 0 | 3,473 | 46,508 | #18 | |
Stanford · university | United States | 0 | 3,016 | 50,896 | #30 | ||
Guangzhou · cancer center | China | none recorded | 0 | 1,866 | 22,263 | none recorded | #60 |
| United Kingdom | none recorded | 1 | 735 | 7,432 | - | ||
| China | none recorded | 0 | 4,969 | 62,764 | - | ||
Philadelphia · cancer center | United States | 0 | 3,148 | 54,267 | - | ||
Shanghai · hospital Programme: Liver Cancer Institute, Liver transplantation for HCC | China | none recorded | 0 | 2,872 | 31,534 | - | |
Wuhan · hospital | China | none recorded | 0 | 2,478 | 31,527 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Hepatocellular carcinoma but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
20 centres are named on one of the types below rather than on Hepatocellular carcinoma itself. Grouped by the type that holds them; the full table for each sits on that type's page.